KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).J Clin OncolPMID 35192411PMC98516892022-Jun-100.95The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, the primary endpoint is a response rate (CR rate), not a time-to-event endpoint. No time-to-event data or analysis (Kaplan-Meier, HR, etc.) are mentioned in the abstract. Therefore, it is excluded.待处理
Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.Arthritis Res TherPMID 35689239PMC91859602022-Jun-100.98未发现恶性肿瘤人群证据。待处理
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.N Engl J MedPMID 35443106PMC90699942022-Jun-090.98未发现恶性肿瘤人群证据。待处理
Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).BMC CancerPMID 35672690PMC91753722022-Jun-080.90The record describes a Phase II randomized trial with a drug intervention (liposomal MTP-PE) and is an original report, but it does not meet the required Phase III/IIIb or Phase II/III designation, and it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as the report focuses on feasibility and design, with no efficacy results.待处理
Efficacy of HP-3070, an Asenapine Transdermal System, on Symptoms of Hostility in Adults With Schizophrenia: A Post Hoc Analysis of a 6-Week Phase 3 Study.J Clin PsychiatryPMID 35687858无 PMCID2022-Jun-060.98未发现恶性肿瘤人群证据。待处理
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.LancetPMID 35644166无 PMCID2022-Jun-040.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.N Engl J MedPMID 35507481PMC91277712022-Jun-020.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.N Engl J MedPMID 35507508PMC91277732022-Jun-020.98未发现恶性肿瘤人群证据。待处理
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.N Engl J MedPMID 35569035无 PMCID2022-Jun-020.98未发现恶性肿瘤人群证据。待处理
Hypericum and neem oil for dehisced post-surgical wounds: a randomised, controlled, single-blinded phase III study.J Wound CarePMID 35678785无 PMCID2022-Jun-020.98未发现恶性肿瘤人群证据。待处理
Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines.Int J Radiat Oncol Biol PhysPMID 35157993无 PMCID2022-Jun-010.85The study is an original result from a phase 3 randomized trial in human cervical cancer, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. It focuses on patterns of relapse and dose comparisons for radiation planning, not drug efficacy. The drug component (chemoradiation) is part of the trial's overall regimen, but this specific analysis is not evaluating drug intervention efficacy.待处理
Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.JAMA CardiolPMID 35416910PMC90085642022-Jun-010.98未发现恶性肿瘤人群证据。待处理
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class.JAMA OncolPMID 35482347PMC90521072022-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.JAMA NeurolPMID 35532908PMC90869352022-Jun-010.98未发现恶性肿瘤人群证据。待处理
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw OpenPMID 35675076PMC91784352022-Jun-010.98未发现恶性肿瘤人群证据。待处理
Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.Obstet GynecolPMID 35675604无 PMCID2022-Jun-010.95The study is a definitive Phase III randomized controlled trial in humans with an oncology-related condition (uterine leiomyoma), but the reported outcomes are pain-related efficacy endpoints, not survival, progression, recurrence, death, hazard, or time-to-event outcomes as required by the adjudication criteria.待处理
Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial.J Autism Dev DisordPMID 34181143无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China.ClimactericPMID 34402360无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.BJU IntPMID 34480522PMC94239392022-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
[The role of proton therapy in esophageal cancer].Cancer RadiotherPMID 34688549无 PMCID2022-Jun0.85The record is a review article discussing proton therapy, which is a radiation therapy modality, not a drug intervention. While it mentions randomized trials, it does not present original results from a specific drug-containing Phase III trial with a time-to-event efficacy endpoint. The phase of the trials discussed is not definitively established as Phase III/IIIb from the provided text, and no drug intervention is evident.待处理
A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study).Clin Lung CancerPMID 34802879无 PMCID2022-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.Mol OncolPMID 34954864PMC91687612022-Jun0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.Clin Breast CancerPMID 34955432无 PMCID2022-Jun0.80The study is a Phase III randomized trial in oncology with a drug intervention and reports primary results. However, it is ineligible because the primary efficacy endpoint is objective response rate (ORR), which is a categorical measure at a fixed timepoint (Week 24), not a time-to-event endpoint. The publication does not report or signal any time-to-event outcome (OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio.待处理
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.Am J OphthalmolPMID 35038415无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial.Lancet Respir MedPMID 35101183无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
A Phase 3, Randomized, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Neu-BoNT/A in Treatment of Primary Axillary Hyperhidrosis.Aesthetic Plast SurgPMID 35132458无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.Diabetes Obes MetabPMID 35187770PMC93149642022-Jun0.98未发现恶性肿瘤人群证据。待处理
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.Ann Rheum DisPMID 35210264无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.Langenbecks Arch SurgPMID 35211831无 PMCID2022-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.GastroenterologyPMID 35227777无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.Int J UrolPMID 35293030PMC93106052022-Jun0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.Eur J Clin InvestPMID 35342931PMC91116592022-Jun0.98未发现恶性肿瘤人群证据。待处理
Results of the COMPARE trial of Constraint-induced or Multimodality Aphasia Therapy compared with usual care in chronic post-stroke aphasia.J Neurol Neurosurg PsychiatryPMID 35396340PMC91489852022-Jun0.98未发现恶性肿瘤人群证据。待处理
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.Adv TherPMID 35397772PMC91230682022-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial.Adv TherPMID 35412227PMC91230402022-Jun0.98未发现恶性肿瘤人群证据。待处理
Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.Adv TherPMID 35429281PMC91230182022-Jun0.98未发现恶性肿瘤人群证据。待处理
Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.Cancer EpidemiolPMID 35429893无 PMCID2022-Jun0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.Eur J CancerPMID 35429901无 PMCID2022-Jun0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.Ann Intern MedPMID 35467935无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes EndocrinolPMID 35468321无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial.Nat MedPMID 35469070无 PMCID2022-Jun0.85The trial meets criteria for oncology, human, randomized, phase 3, and drug intervention. However, it fails the key eligibility criterion of having a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as defined in the adjudication instructions. The reported endpoints are clinical and patient-centered outcomes, not survival or progression-free survival time-to-event analyses.待处理
Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.Rev Esp Enferm DigPMID 35469409无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.Lancet OncolPMID 35489363PMC102841182022-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.Aliment Pharmacol TherPMID 35505467无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.Respir MedPMID 35512458无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.Lancet NeurolPMID 35525250无 PMCID2022-Jun0.98未发现恶性肿瘤人群证据。待处理
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.Lancet HaematolPMID 35550060无 PMCID2022-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet OncolPMID 35576956无 PMCID2022-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers.Drugs R DPMID 35635717PMC91674182022-Jun0.98未发现恶性肿瘤人群证据。待处理
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.ESMO OpenPMID 35653981PMC92714772022-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理